Stellar Biotechnologies to Host Corporate Update and Second Quarter 2014 Results Conference Call on April 10
04 April 2014 - 3:00PM
Marketwired
Stellar Biotechnologies to Host Corporate Update and Second Quarter
2014 Results Conference Call on April 10
PORT HUENEME, CA--(Marketwired - Apr 4, 2014) - Stellar
Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF)
(TSX-VENTURE: KLH), the world leader in sustainable manufacture of
Keyhole Limpet Hemocyanin ("KLH"), will host a general corporate
update conference call and webcast at 1:30 PM ET (10:30 AM PT) on
April 10, 2014.
Telecast and Webcast Information: Date: Thursday, April 10, 2014
Time: 1:30 PM ET/ 10:30 AM PT US Dial-in (Toll-free):
1-480-629-9712 International Dial-in: 1-480-629-9712 Conference
Call ID: 4678236 Webcast Link:
http://public.viavid.com/index.php?id=108588
For the live and archived webcast, please visit the investor
presentation section on Stellar Biotechnologies' website at:
www.stellarbiotech.com
A replay of the call will be available through 24 April 2014. To
access the replay, please call 1-877-870-5176 if calling from North
America and 1-858-384-5517 if calling from outside the U.S. and
Canada. The replay passcode is 4678236. The webcast will also be
archived on the Company website. For additional information please
visit the investor section at www.stellarbiotech.com.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-VENTURE: KLH) (OTCQB: SBOTF)
is the world leader in sustainable manufacture of Keyhole Limpet
Hemocyanin (KLH), an important immune-stimulating protein used in
wide-ranging therapeutic and diagnostic markets. KLH is both an
active pharmaceutical ingredient (API) in many new immunotherapies
(targeting cancer, infectious diseases, and immune disorders) as
well as a finished product for measuring immune status. Stellar
Biotechnologies is unique in its proprietary methods, facilities,
and KLH technology. We are committed to meeting the growing demand
for commercial-scale supplies of GMP grade KLH, ensuring
environmentally sound KLH production, and developing KLH-based
active immunotherapies.
To receive regular updates, enter email at
http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH knowledge base
www.KLHsite.org.
Forward Looking Statements There can be no assurance that
forward-looking statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Readers should not place undue
reliance on such statements. Except in accordance with applicable
securities laws, the Company expressly disclaims any obligation to
update any forward-looking statements or forward-looking statements
that are incorporated by reference herein. This news release does
not constitute an offer to sell, or a solicitation of an offer to
buy any of the Company's securities set out herein in the United
States, or to, or for the benefit or account of, a U.S. Person or
person in the United States. Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of these releases.
Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Stellar Biotechnologies, Inc. (TSXV:KLH)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
